Keyphrases
Proton Pump Inhibitors
100%
Telepharmacy
100%
Pharmacist
91%
Type 2 Diabetes Mellitus (T2DM)
69%
Metformin
66%
Clinical Outcomes
66%
COVID-19
63%
Army
55%
Type 2 Diabetic Patients
43%
Medical Records
41%
COVID-19 Severity
41%
COVID-19 Patients
41%
Indonesia
41%
Antidiabetic Drugs
40%
Therapeutic Drug Monitoring
36%
Medicines Optimisation
33%
Medication-related Problems
33%
Doxorubicin
33%
General Practitioner Practice
33%
Hair Growth Promoter
33%
ABO Blood Group
33%
Doxorubicinol
33%
Gastrointestinal Side Effects
33%
ACE2 Gene
33%
Hibiscus
33%
Inappropriate Use
33%
Cognitive Function
33%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
33%
Type 2 Diabetes Mellitus Patients
33%
Sulfonylurea
33%
Cardiotoxicity
33%
Breast Cancer
33%
Volumetric Absorptive Microsampling
33%
United Kingdom
33%
Clinical Treatment
33%
Patient Perception
33%
4-hydroxycyclophosphamide
33%
Clinical Profile
33%
United States
33%
Leaf Extract
33%
Single-center Retrospective Study
33%
Cyclophosphamide
33%
Multicenter Randomized Controlled Trial
33%
ACE Gene
33%
Cancer Patients
33%
Patient Plasma
33%
Genotype Variation
33%
Potential Drug Interactions
33%
Single-center Study
33%
Clinical Response
33%
Pharmacology, Toxicology and Pharmaceutical Science
Proton Pump Inhibitor
100%
Comorbidity
66%
Randomized Controlled Trial
66%
Non Insulin Dependent Diabetes Mellitus
66%
Drug Interaction
50%
Cross-Sectional Study
50%
Therapeutic Drug Monitoring
36%
Diabetes Mellitus
35%
Breast Cancer
33%
Ureaplasma
33%
Growth Promotor
33%
Hibiscus
33%
Polypharmacy
33%
Cardiotoxicity
33%
Chronic Kidney Failure
33%
Microemulsion
33%
Infection
33%
Malignant Neoplasm
33%
Retrospective Study
33%
Antihypertensive Agent
33%
Camellia Sinensis
33%
Doxorubicin
33%
Doxorubicinol
33%
4-Hydroxycyclophosphamide
33%
Metformin
33%
Multiple Chronic Conditions
33%
Cyclophosphamide
33%
Antidiabetic Agent
33%
Pandemic
33%
Health Status
33%
Gastrointestinal Symptom
33%
Tocilizumab
33%
Side Effect
33%
Constipation
22%
Medical Prescription
16%
Isotopes of Potassium
16%
Mortality Rate
16%
Pharmacotherapy
16%
Alanine Aminotransferase
16%
Clinical Feature
16%
SARS Coronavirus
16%
Creatinine
16%
Combination Therapy
16%
Biological Marker
16%
Favipiravir
16%
Remdesivir
16%
Adverse Drug Reaction
16%
Pharmaceutical Care
16%
Diseases
14%
Semicarbazide
13%
